Skip to main content
Clinical Trials/NCT05703243
NCT05703243
Recruiting
N/A

Discovering Novel Cancer Treatment Options Using a Comprehensive NGS-based Liquid Molecular Testing Panel in the Community Setting. ("DINOSAur II")

Glendale Adventist Medical Center d/b/a Adventist Health Glendale1 site in 1 country572 target enrollmentFebruary 1, 2023

Overview

Phase
N/A
Intervention
Not specified
Conditions
Stage III Solid Tumors
Sponsor
Glendale Adventist Medical Center d/b/a Adventist Health Glendale
Enrollment
572
Locations
1
Primary Endpoint
European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (QLQ-C30)
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

To prospectively identify cancer patients whose tumors express specific molecular markers targeted by therapeutic agents from a comprehensive l i q u i d molecular test, for the purpose of selecting the most clinically appropriate treatment in a pragmatic two arm trial.

Registry
clinicaltrials.gov
Start Date
February 1, 2023
End Date
January 1, 2025
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Glendale Adventist Medical Center d/b/a Adventist Health Glendale
Responsible Party
Principal Investigator
Principal Investigator

Mihran Shirinian

Principal Investigator

Glendale Adventist Medical Center d/b/a Adventist Health Glendale

Eligibility Criteria

Inclusion Criteria

  • Patients who have given informed consent in accordance with the methods and procedures of this study
  • Diagnosis of cancer (stage 3 and stage 4; solid tumors only) requiring medical care
  • Patients who have not received treatment related to his/her cancer
  • Patients who are willing to sign a release of medical records to the research team
  • Male and female patients ≥18 years of age
  • Patients under oncology care
  • Sufficient clinical status for collection of blood sample within usual care

Exclusion Criteria

  • Patients considered minors in the jurisdiction where the protocol is conducted
  • Patients who are prisoners and pregnant women
  • Patients who cannot provide consent and did not sign a power of attorney

Outcomes

Primary Outcomes

European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (QLQ-C30)

Time Frame: 2 years

The EORTC Core Questionnaire (QLQ-C30) includes six clearly distinguishable functioning scales that have been thoroughly tested and validated on an international level and that are available in 110 different language versions. The scaling of items is 1 (Not at all) to 4 (Very much), 1 (Very poor) to 7 (Excellent). The higher the score the better the quality of life.

Secondary Outcomes

  • Compare the proportion of enrolling in clinical trials(2 years)

Study Sites (1)

Loading locations...

Similar Trials